GPR78 is a member of the G protein-coupled receptor (GPCR) family, which plays a critical role in mediating cellular responses to external signals. GPCRs are involved in a vast array of physiological processes, including sensory perception, immune responses, and neurotransmission. Specifically, GPR78 is implicated in various intracellular signaling cascades that regulate cell proliferation, differentiation, and survival. The exact physiological ligands and signaling pathways associated with GPR78 are still under investigation, but like other GPCRs, it is presumed to participate in the finely tuned orchestration of cellular communication and response mechanisms. The ability of GPR78 to affect such a wide range of cellular processes highlights its potential importance in maintaining cellular homeostasis and responding to environmental changes.
The inhibition of GPR78, similar to other GPCRs, can be achieved through several molecular mechanisms that prevent the receptor from activating its associated G proteins and initiating downstream signaling pathways. One common approach involves the use of small molecule antagonists that bind to the ligand-binding domain of GPR78, blocking the interaction with its natural ligands and thus inhibiting receptor activation. Another strategy is the development of allosteric modulators that bind to sites other than the ligand-binding domain, inducing conformational changes that reduce the receptor's ability to engage G proteins effectively. Additionally, genetic approaches such as RNA interference (RNAi) can be employed to decrease the expression levels of GPR78, thereby reducing its functional presence on the cell surface. Targeting the receptor for degradation through the manipulation of the ubiquitin-proteasome pathway represents another avenue for inhibiting GPR78 function. These strategies for GPR78 inhibition not only provide valuable tools for elucidating the biological functions of this GPCR but also contribute to the broader understanding of GPCR-mediated signaling pathways in health and disease.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
A beta-adrenergic agonist that elevates cAMP levels by stimulating adenylate cyclase, potentially resulting in the activation of cAMP-dependent pathways that regulate GPR78. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Binds to its respective G-protein-coupled receptors, leading to increased intracellular cAMP, which can trigger signaling pathways activating proteins such as GPR78. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
A non-selective inhibitor of phosphodiesterases, leading to increased cAMP levels that can activate signaling pathways involving GPR78. | ||||||
L-Arginine | 74-79-3 | sc-391657B sc-391657 sc-391657A sc-391657C sc-391657D | 5 g 25 g 100 g 500 g 1 kg | $20.00 $31.00 $61.00 $219.00 $352.00 | 2 | |
Precursor for nitric oxide synthesis, which can activate guanylate cyclase and increase cGMP levels, indirectly affecting pathways that may lead to GPR78 activation. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
A selective inhibitor of phosphodiesterase 5 (PDE5), which increases cGMP levels, potentially leading to activation of signaling cascades that involve GPR78. | ||||||
Adenosine | 58-61-7 | sc-291838 sc-291838A sc-291838B sc-291838C sc-291838D sc-291838E sc-291838F | 1 g 5 g 100 g 250 g 1 kg 5 kg 10 kg | $34.00 $48.00 $300.00 $572.00 $1040.00 $2601.00 $4682.00 | 1 | |
Through its receptors, increases intracellular cAMP levels, which can activate PKA and lead to the activation of downstream targets including GPR78. | ||||||
PACAP(6-38) | 137061-48-4 | sc-391136 sc-391136A | 500 µg 1 mg | $540.00 $932.00 | ||
Activates adenylate cyclase through its receptor, increasing cAMP and potentially activating downstream proteins such as GPR78. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Inhibits PDE4, leading to increased cAMP levels and activation of PKA-dependent pathways, which may include the activation of GPR78. | ||||||